Peripheral artery disease is one of the most serious complications affecting people with type 2 diabetes. The condition develops when arteries in the legs become narrowed, reducing blood flow to the feet and lower limbs.
People may notice leg pain while walking, numbness, slow-healing sores, or skin changes. If blood flow becomes critically low, amputation may become necessary. Doctors have relatively few treatment options that can slow the progression of PAD, making new discoveries especially important.
Researchers from Cleveland Clinic have now reported that GLP-1 receptor agonist medicines could provide significant protection for these high-risk patients. Their findings were published in the Journal of the American Heart Association.
Instead of conducting a clinical trial, the investigators analysed health records from more than 2,000 adults who had both type 2 diabetes and PAD. They compared patients treated with GLP-1 receptor agonists against similar patients treated with metformin, the world’s most commonly prescribed diabetes medicine.
After analysing the records, the researchers found that people receiving GLP-1 medicines consistently experienced better long-term outcomes. Overall death rates were 26 percent lower. Hospitalizations fell by 13 percent.
The chance of needing an amputation was reduced by as much as 48 percent, while procedures to reopen blocked arteries were reduced by 36 percent. The two groups had similar rates of heart attack, stroke, and serious kidney disease.
According to the researchers, the strongest benefits appeared among people with advanced PAD and those living with obesity. Obesity increases inflammation, damages blood vessels, and worsens insulin resistance, all of which may speed up artery disease. GLP-1 medicines may help by lowering inflammation, improving blood vessel health, reducing body weight, and controlling blood sugar.
GLP-1 receptor agonists have already become well known for treating diabetes and obesity. Medicines in this group include semaglutide, sold under the brand names Ozempic and Wegovy, along with several similar drugs. Scientists continue to discover additional health benefits beyond glucose control.
Experts who were not involved in the study described the findings as promising but also urged caution. Because the research looked back at existing medical records, it cannot prove that the medicine itself was responsible for the improved outcomes.
Other patient differences may have contributed. Carefully designed clinical trials are still needed to confirm whether these medicines directly reduce amputations and improve survival.
This study provides encouraging evidence that GLP-1 receptor agonists could become an important treatment option for patients living with both type 2 diabetes and peripheral artery disease. The large reductions in amputation and death deserve further investigation.
However, observational studies cannot replace randomized clinical trials. If future studies confirm these results, GLP-1 medicines could become an even more valuable part of caring for people with severe circulation problems in the legs.
If you care about diabetes, please read studies about Vitamin D and type 2 diabetes, and to people with diabetes, some fruits are better than others.
For more health information, please see recent studies that low calorie diets may help reverse diabetes, and 5 vitamins that may prevent complication in diabetes.
Source: Cleveland Clinic.
